In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice

Gene Therapy

Volumn 8, Issue 16, 2001, Pages 1234-1240

  Kishida, T ^a   Asada, H ^a   Satoh, E ^a   Tanaka, S ^a   Shinya, M ^a   Hirai, H ^a   Iwai, M ^a   Tahara, H ^b   Imanishi, J ^a   Mazda, O ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cytokine; Electroporation; Episomal vector; Epstein Barr virus based vector; Gene therapy; Melanoma

Indexed keywords

ANTINEOPLASTIC AGENT; CELL NUCLEUS ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; LUCIFERASE; PLASMID VECTOR; VIRUS ANTIGEN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL ACTIVITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG BLOOD LEVEL; DRUG EFFICACY; ELECTROPORATION; EPSTEIN BARR VIRUS; FEMALE; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSFECTION; IMMUNE RESPONSE; IN VIVO STUDY; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TRANSGENE;

ANIMALS; ELECTROPORATION; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; GENE THERAPY; GENETIC VECTORS; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-18; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PLASMIDS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 17944369209     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301519     Document Type: Article

References (54)

1. Cytokine gene therapy of cancer using interleukin-12: Murine and clinical trials
2. Cytokine therapy for cancer
3. In vivo gene delivery by electroporation
4. Long-term, high level in vivo gene expression after electric pulse-mediated gene transfer into skeletal muscle
5. Gene transfer into muscle by electroporation in vivo
6. Direct gene transfer into rat liver cells by in vivo electroporation
7. In vivo efficacy and safety of skin electroporation
8. Targeted gene transfer to corneal endothelium in vivo by electric pulse
9. In vivo electrically mediated protein and gene transfer in murine melanoma
10. Electrically mediated plasmid DNA delivery to hepatocellular carcinomas in vivo
11. Gene delivery with optimized electroporation parameters shows potential for treatment of gliomas
12. Highly efficient electro-gene therapy of solid tumor by using an expression plasmid for the herpes simplex virus thymidine kinase gene
13. Interleukin-12 as an inducer of cytotoxic effectors in anti-tumor immunity
14. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes
15. Regulation of human cytolytic lymphocyte responses by interleukin-12
16. Cloning of a new cytokine that induces IFN-γ production by T cells
17. The importance of electric field distribution for effective in vivo electroporation of tissues
18. Potent antitumor effects mediated by local expression of the mature form of the interferon-γ inducing factor, interleukin-18 (IL-18)
19. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12
20. Impaired tumorigenicity of human pancreatic cancer cells retrovirally transduced with interleukin-12 or interleukin-15 gene
21. Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells
22. Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level
23. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus
24. Intratracheal administration of interleukin 12 plasmid-cationic lipid complexes inhibits murine lung metastases
25. Gene transfer in vitro and in vivo with Epstein-Barr virus-based episomal vector results in markedly high transient expression in rodent cells
26. Effective suicide gene therapy in vivo by EBV-based plasmid vector coupled with polyamidoamine dendrimer
27. Direct intra-cardiomuscular transfer of β2-adrenergic receptor gene augments cardiac output in cardiomyopathic hamsters
28. Efficient gene transduction by Epstein-Barr virus-based vectors coupled with cationic liposome and HVJ-liposome
29. Highly efficient suicide gene expression in hepatocellular carcinoma cells by Epstein-Barr virus-based plasmid vectors combined with polyamidoamine dendrimer
30. Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoter
31. In vivo gene transfer into rat heart with Epstein-Barr virus-based episomal vectors using a gene gun
32. Functional domains of Epstein-Barr virus nuclear antigen EBNA-1
33. Epstein-Barr virus nuclear antigen 1 forms a complex with the nuclear transporter karyopherin α2
34. A nuclear matrix attachment region organizes the Epstein-Barr viral plasmid in Raji cells into a single DNA domain
35. Multiple EBNA1-binding sites are required to form an EBNA1-dependent enhancer and to activate a minimal replicative origin within oriP of Epstein-Barr virus
36. A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection
37. An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene
38. oriP is essential for EBNA gene promoter activity in Epstein-Barr virus-immortalized lymphoblastoid cell lines
39. Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18
40. Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1β converting enzyme cDNA
41. Mechanism of interleukin 12-mediated toxicities during experimental viral infections: Role of tumor necrosis factor and glucocorticoids
42. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma
43. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma
44. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer
45. Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: Critical role of natural killer cell interferon-γ production and STAT-mediated signal transduction
46. Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy
47. Antitumor electrochemotherapy: New advances in the clinical protocol
48. Bleomycin-mediated electrochemotherapy of basal cell carcinoma
49. Electrically enhanced drug delivery for the treatment of soft tissue sarcoma
50. Epstein-Barr virus strategy in normal and neoplastic B cells
51. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1
52. Efficient selection for high-expression transfectants with a novel eukaryotic vector
53. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells
54. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12